Latest news with #TNF-α
Time of India
4 days ago
- Health
- Time of India
NIN study finds bamboo rice eases rheumatoid arthritis symptoms
Hyderabad: Bamboo rice, the edible seeds of Bambusa arundinacea, demonstrated anti-inflammatory effects in a study conducted on laboratory rats which were experimentally induced with rheumatoid arthritis by researchers from the ICMR-National Institute of Nutrition (NIN), Hyderabad. The study, led by Rajendran Ananthan from the division of food chemistry, appeared in the May 2025 edition of 'Food and Humanity of Science Direct'. It examined the impact of bamboo rice on live Wistar rats induced with arthritis. Though these findings are limited to animal models, they support traditional beliefs among tribal communities in India's Southwestern Ghats, where bamboo rice is used to manage joint pain and inflammation. The authors emphasise that while the data point toward therapeutic value, further studies are required to explore the bioavailability and specific mechanisms of action of the grain's active compounds. Over 55 days, the rats were given diets containing varying proportions of bamboo rice flour, alongside standard treatment with indomethacin. Researchers observed significant reductions in paw swelling, improved body weight, and normalised spleen indices in rats treated with bamboo rice. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo Histological examination of ankle joints confirmed a reduction in pannus formation, synovial hyperplasia, and inflammation. Radiological and biochemical tests supported these results. Gene expression analysis revealed that bamboo rice suppressed levels of tumour necrosis factor-alpha (TNF-α), a cytokine associated with inflammation in rheumatoid arthritis. The grain's rich phytochemical content, including flavonoids and phytosterols, was identified as a likely contributor to its observed therapeutic effects. The study also examined the influence of bamboo rice on serum Rheumatoid Factor (RF), an important marker in the diagnosis and progression of rheumatoid arthritis. While baseline RF levels in arthritic rats were only modestly elevated, medium and high-dose bamboo rice groups showed a significant reduction. This aligns with the outcomes of similar studies involving natural plant extracts. This preliminary research offers a scientific basis for the traditional use of bamboo rice and suggests its potential role as a dietary intervention in managing rheumatoid arthritis.
See - Sada Elbalad
23-05-2025
- Health
- See - Sada Elbalad
Air Pollution and Skin Damage: What You Need to Know
Taarek Refaat Recent research has increasingly confirmed the damaging effects of air pollution on skin health. Air pollutants impact the skin through several interconnected biological and chemical pathways, leading to both acute irritation and chronic skin disorders. Over time, this contributes to chronic skin conditions such as eczema, acne, and melasma, while also increasing susceptibility to infections and environmental allergens. Climate change and air pollution together pose serious risks to skin health. Increased UV exposure and heat from climate change weaken the skin, while pollutants like PM2.5 and ozone trigger inflammation, aging, and skin disorders. Oxidative Stress Air pollution triggers oxidative stress in the skin by generating reactive oxygen species (ROS) that overwhelm the body's natural antioxidant defenses. Pollutants such as particulate matter, ozone, and nitrogen dioxide penetrate the skin or interact on its surface, initiating harmful chemical reactions. This oxidative stress damages lipids, proteins, and DNA within skin cells, leading to inflammation and premature aging. It also breaks down collagen and elastin, resulting in wrinkles and loss of skin firmness. The skin barrier becomes compromised, making it more vulnerable to dryness, irritation, and infections. Long-term exposure can worsen conditions like eczema, acne, and hyperpigmentation. Inflammatory Pathways Activation Air pollution activates inflammatory pathways in the skin by stimulating immune receptors such as Toll-like receptors (TLRs) and the aryl hydrocarbon receptor (AhR). When pollutants like particulate matter and nitrogen dioxide interact with these receptors, they trigger the release of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α. This inflammatory response causes redness, swelling, and irritation, contributing to flare-ups of chronic skin conditions like eczema, psoriasis, and acne. Persistent inflammation also damages skin cells and disrupts normal skin function, accelerating aging and weakening the skin's barrier. Aryl Hydrocarbon Receptor Activation The aryl hydrocarbon receptor is a key skin receptor activated by pollutants like polycyclic aromatic hydrocarbons (PAHs) and dioxins found in air pollution. When activated, AhR alters gene expression related to skin pigmentation, immune responses, and detoxification processes. This activation increases the production of reactive oxygen species, leading to oxidative stress and inflammation. AhR signaling can disrupt the skin barrier, promote hyperpigmentation, and contribute to chronic skin conditions such as atopic dermatitis and psoriasis. Long-term AhR activation is also linked to premature aging and may increase the risk of skin cancer. Targeting AhR pathways is a growing focus in skincare research to mitigate pollution-related skin damage. Skin Barrier Disruption The skin barrier acts as the body's first line of defense, protecting against environmental toxins, pathogens, and moisture loss. It maintains hydration by preventing water evaporation and helps regulate skin temperature. A healthy barrier supports immune responses and keeps the skin resilient. When disrupted, it leads to dryness, irritation, and increased sensitivity. Recent research shows that air pollution, especially fine particulate matter, damages the skin barrier by increasing water loss and allowing harmful substances to penetrate more easily. This disruption worsens skin conditions like eczema and psoriasis. Pollutants also activate inflammatory pathways, which further harm the skin's defense. DNA Damage and Mutagenesis Air pollution damages skin DNA by generating reactive oxygen species and exposing cells to harmful pollutants, causing mutations and increasing risks of aging and skin cancer. The skin has natural DNA repair mechanisms that help fix damage caused by air pollution. However, chronic pollution can overwhelm these mechanisms, leading to genetic damage buildup. Supporting DNA repair with antioxidants, protective skincare, and reducing pollution exposure helps maintain healthier skin. Microbiome Dysbiosis Recent research has shown that air pollution significantly disrupts the skin's microbiome, leading to dysbiosis—a harmful imbalance of microbial communities. Recent studies highlight how exposure to particulate matter and nitrogen dioxide reduces beneficial bacteria diversity, weakening the skin's protective barrier. This microbial imbalance increases susceptibility to inflammation, infections, and chronic skin conditions such as acne, eczema, and psoriasis. Researchers also found that pollutants promote the growth of harmful bacteria, further aggravating skin irritation and sensitivity. Advanced sequencing techniques confirm that pollution alters microbial gene expression, affecting skin immune responses. Mitochondrial Dysfunction Mitochondria are essential for skin health as they produce the energy (ATP) required for cell growth, repair, and regeneration. They regulate cellular metabolism and help maintain the skin's barrier function and elasticity. By controlling reactive oxygen species, mitochondria balance important cell signaling and defense mechanisms. When mitochondrial function declines, energy production decreases and oxidative damage increases, impairing skin renewal and contributing to aging, inflammation, and various skin disorders. Recent research reveals that air pollution causes mitochondrial dysfunction by increasing oxidative stress and damaging mitochondrial DNA. Pollutants like particulate matter and ozone reduce mitochondrial efficiency, leading to excess ROS that further harm skin cells. This creates a vicious cycle of damage, accelerating skin aging, dryness, and loss of elasticity. Chronic mitochondrial dysfunction is also linked to skin diseases such as psoriasis and eczema. Air Pollution and Eczema Air pollution is a significant trigger that can worsen eczema symptoms by damaging the skin barrier and increasing inflammation. Pollutants such as particulate matter, nitrogen dioxide, and ozone penetrate the skin, leading to oxidative stress and immune system activation. This weakens the skin's defenses, making it more susceptible to irritation, dryness, and allergic reactions common in eczema. Studies show that people living in highly polluted areas often experience more frequent and severe eczema flare-ups. The Effects of Tobacco Smoke and Air Pollution on Skin Tobacco smoke is a significant source of indoor air pollution that harms the skin's health and appearance. It contains thousands of toxic chemicals and free radicals that accelerate aging by breaking down collagen and elastin fibers. This leads to wrinkles, dryness, dullness, and slower wound healing. Tobacco smoke also increases oxidative stress and triggers inflammation, which can worsen skin conditions like psoriasis and eczema. When combined with outdoor air pollution, the harmful effects on skin are amplified, further weakening the skin barrier. Chronic exposure can result in premature aging and higher susceptibility to infections. Skincare Tips to Fight Air Pollution To protect the skin from air pollution and tobacco smoke, it's essential to combine proper skincare, nutrition, and environmental awareness. Daily cleansing helps remove pollutants, including smoke particles, and prevents clogged pores—especially when using gentle products rich in antioxidants like green tea or niacinamide. Topical antioxidants such as vitamins C and E, along with barrier-repairing moisturizers, strengthen the skin's defense against oxidative stress. Sunscreen remains crucial, as UV rays combined with air pollutants and tobacco toxins accelerate skin aging and inflammation. Some modern sunscreens include anti-pollution compounds for enhanced protection. Internally, a balanced diet rich in antioxidants—fruits, vegetables, and whole grains—along with good hydration supports skin resilience. At home, using air purifiers, avoiding indoor smoke (including tobacco smoke), and ensuring proper ventilation can significantly lower exposure. Monitoring air quality indexes, avoiding outdoor activities during high pollution levels, and wearing protective clothing are also vital. These steps help preserve skin health and reduce the risk of premature aging, irritation, and pollution-related skin disorders. read more Analysis- Turkey Has 0 Regional Allies... Why? Analysis: Russia, Turkey... Libya in Return For Syria? Analysis: Who Will Gain Trump's Peace Plan Fruits? Analysis: Will Turkey's Erdogan Resort to Snap Election? Analysis: What Are Turkey's Aspirations in Iraq? Opinion & Analysis Analysis: Mercenaries In Libya... Who Should Be Blamed? Opinion & Analysis Analysis- How 'Libya Nightmare' Takes Erdogan to Algiers Opinion & Analysis Analysis: What Happens After Brexit? Opinion & Analysis Analysis: Strategic Significance of Libya's Sirte, Jufra! News Egypt confirms denial of airspace access to US B-52 bombers News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia News Australia Fines Telegram $600,000 Over Terrorism, Child Abuse Content Arts & Culture Nicole Kidman and Keith Urban's $4.7M LA Home Burglarized Sports Former Al Zamalek Player Ibrahim Shika Passes away after Long Battle with Cancer Sports Neymar Announced for Brazil's Preliminary List for 2026 FIFA World Cup Qualifiers News Prime Minister Moustafa Madbouly Inaugurates Two Indian Companies Arts & Culture New Archaeological Discovery from 26th Dynasty Uncovered in Karnak Temple Business Fear & Greed Index Plummets to Lowest Level Ever Recorded amid Global Trade War Arts & Culture Zahi Hawass: Claims of Columns Beneath the Pyramid of Khafre Are Lies
Associated Press
08-05-2025
- Business
- Associated Press
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
BALTIMORE--(BUSINESS WIRE)--May 8, 2025-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The study series is expected to evaluate the impact of the Company's novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management in patients who are a) on GLP-1 agonists, b) candidates for treatment with GLP-1 agonists, or c) probably not suitable for treatment with weight loss therapy. In coordination with Renova Health, the purpose of this first stage was to analyze 30,000 patients already under the care of primary care physicians and identify convergences between the use of GLP-1 agonists and chronic disorders linked with increased risk of inflammation. The data were parsed into three cohorts depending on prespecified criteria. TNF plans to use these data to optimize appropriate patient recruitment and accelerate isomyosamine drug development. TNF's President and Chief Medical Officer, Mitchell Glass, M.D., commented, 'Our goal for our GLP-1 study series is to identify patients who are taking GLP-1 agonists to test whether isomyosamine can decrease inflammation and prevent or ameliorate the risk of adverse outcomes such as muscle wasting in patients who have baseline TNF-derived inflammatory signals. In our initial review of the data, we have already noted that sarcopenia and frailty are both underreported, which we believe provides evidence that at-risk populations could suffer adverse events from GLP-1 treatment without adequate surveillance to detect and treat drug-induced muscle wasting.' 'The prevalence of certain disorders such as sarcopenia were well below the Centers for Disease Control and Prevention's estimates in community dwelling adults,' said Dave Jacobs, Chief Executive Officer of Renova Health. 'Identifying patients in the community who are at increased risk of fall may enable us to use non-invasive monitoring to identify these patients earlier and more accurately and to provide support. We believe early and ongoing evaluation of sarcopenic and frail patients could enable us to impact quality of life in thousands of patients once identified and followed with straightforward and validated tests of balance and cognition.' About Renova Health Renova Health partners with large clinic practices, hospital systems, and accountable care organizations to help deliver better patient outcomes at a lower cost. The key to Renova Health's success is its highly skilled, caring, and passionate Personal Health Advocates that create and nurture a personal, trusting relationship with patients that helps to uncover deeper insights and ultimately leads to superior healthcare outcomes. For more information, visit About Isomyosamine Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNF-α plays a causative role in the pathogenesis of various age-related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's goals and expectations related to the Company's partnership with Renova Health. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on CONTACT: Investor Contact: Robert Schatz (646) 421-9523 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MARYLAND INDUSTRY KEYWORD: RESEARCH TECHNOLOGY CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY PHARMACEUTICAL HEALTH SCIENCE ARTIFICIAL INTELLIGENCE OTHER SCIENCE SOURCE: TNF Pharmaceuticals, Inc. Copyright Business Wire 2025. PUB: 05/08/2025 09:20 AM/DISC: 05/08/2025 09:19 AM
Business Wire
08-05-2025
- Business
- Business Wire
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results from the first stage of a general practice population study focusing on patients receiving GLP-1 agonists. The study series is expected to evaluate the impact of the Company's novel oral TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in preserving lean muscle mass during and after GLP-1 treatment for weight loss and chronic weight management in patients who are a) on GLP-1 agonists, b) candidates for treatment with GLP-1 agonists, or c) probably not suitable for treatment with weight loss therapy. In coordination with Renova Health, the purpose of this first stage was to analyze 30,000 patients already under the care of primary care physicians and identify convergences between the use of GLP-1 agonists and chronic disorders linked with increased risk of inflammation. The data were parsed into three cohorts depending on prespecified criteria. TNF plans to use these data to optimize appropriate patient recruitment and accelerate isomyosamine drug development. TNF's President and Chief Medical Officer, Mitchell Glass, M.D., commented, 'Our goal for our GLP-1 study series is to identify patients who are taking GLP-1 agonists to test whether isomyosamine can decrease inflammation and prevent or ameliorate the risk of adverse outcomes such as muscle wasting in patients who have baseline TNF-derived inflammatory signals. In our initial review of the data, we have already noted that sarcopenia and frailty are both underreported, which we believe provides evidence that at-risk populations could suffer adverse events from GLP-1 treatment without adequate surveillance to detect and treat drug-induced muscle wasting.' 'The prevalence of certain disorders such as sarcopenia were well below the Centers for Disease Control and Prevention's estimates in community dwelling adults,' said Dave Jacobs, Chief Executive Officer of Renova Health. 'Identifying patients in the community who are at increased risk of fall may enable us to use non-invasive monitoring to identify these patients earlier and more accurately and to provide support. We believe early and ongoing evaluation of sarcopenic and frail patients could enable us to impact quality of life in thousands of patients once identified and followed with straightforward and validated tests of balance and cognition.' About Renova Health Renova Health partners with large clinic practices, hospital systems, and accountable care organizations to help deliver better patient outcomes at a lower cost. The key to Renova Health's success is its highly skilled, caring, and passionate Personal Health Advocates that create and nurture a personal, trusting relationship with patients that helps to uncover deeper insights and ultimately leads to superior healthcare outcomes. For more information, visit About Isomyosamine Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNF-α plays a causative role in the pathogenesis of various age-related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's goals and expectations related to the Company's partnership with Renova Health. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Yahoo
16-04-2025
- Business
- Yahoo
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025
Positive clinical data validates commencement of a larger Phase 2b clinical trial in elderly patients post-hip fracture Drug shown to decrease biomarkers associated with TNF-alpha activation in elderly patients with sarcopenia BALTIMORE, April 16, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled "Isomyosamine for the Treatment of Sarcopenia in Older Adults" was delivered by Mitchell Glass, M.D., President and Chief Medical Officer of TNF, at the British Geriatrics Society (BGB) Spring Meeting 2025, held April 9-11, 2025, in Belfast, Ireland and online. During his presentation, Dr. Glass spoke about the Company's small-molecule TNF-alpha (TNF-α) inhibitor, isomyosamine, which has shown potential for regulating pro-inflammatory cytokines associated with sarcopenia. In response to a question, he emphasized the Company's commitment to sarcopenia as an initial indication, including muscle wasting as an effect of treatment with GLP-1 agonists. He also commented on the Company's plans to extend Phase 3 into the UK and Europe. "An earlier Phase 2 study of isomyosamine demonstrated its safety and tolerability in elderly patients with sarcopenia, with significant reductions in inflammatory biomarkers such as TNF-α, IL-6, and soluble TNF receptor 1 (sTNFR1). We are currently enrolling patients in a larger Phase 2b clinical trial that will investigate isomyosamine's effect on cellular inflammation and recovery of ambulation speed in elderly patients post-hip fracture. An increased sample size and more frequent dosing in the follow-up trial will enable us to better evaluate the drug's potential to improve both clinical and biochemical outcomes in sarcopenic patients," Dr. Glass explained. The British Geriatrics Society is the membership association for professionals specializing in the healthcare of older people across the UK. Founded in 1947, BGS has over 5,000 members, and it is the only Society in the UK offering specialist expertise in the wide range of healthcare needs of older people. About Isomyosamine Isomyosamine (ICD-10-CM code M62.84) is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNFα plays a causative role in the pathogenesis of various age-related diseases. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company's ability to launch and the timing of the Company's planned trial of isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Investor Contact: Robert Schatz(646) 421-9523rschatz@
